Tamoxifen ameliorates symptoms of Duchenne muscular dystrophy

January 15, 2013
The mice were allowed to grasp a metal wire maintained horizontally above a thick layer of soft bedding (upper left). After exploring the wire for a short period of time (upper right), the mice tried to pull themselves on the wire (bottom left), a very energy-demanding exercise, until they lost grip of their hind paws and hung onto the wire with their forelimbs only (bottom right). From this position, the untreated mdx5Cv mice were unable to sustain their own body weight for more than a few seconds before falling, whereas the mdx5Cv mice treated with tamoxifen (not shown) performed much better and as well as normal mice. Credit: Dorchies et al.

A new study has found that tamoxifen, a well-known breast cancer drug, can counteract some pathologic features in a mouse model of Duchenne muscular dystrophy (DMD). At present, no treatment is known to produce long-term improvement of the symptoms in boys with DMD, a debilitating muscular disorder that is characterized by progressive muscle wasting, respiratory and cardiac impairments, paralysis, and premature death. This study will be published in the February 2013 issue of The American Journal of Pathology.

Using the mdx5Cv mouse model of DMD, investigators found that tamoxifen, given orally for more than a year, "caused remarkable improvements of and of diaphragm and cardiac structure," according to lead author Olivier M. Dorchies, PhD, of the Department of Pharmacology, Geneva-Lausanne School of Pharmaceutical Sciences of the University of Geneva and University of Lausanne. For instance, in the heart, fibrosis was diminished by approximately 50%. In the diaphragm, the muscle of the dystrophic mouse thought to be most like that of human DMD, tamoxifen reduced fibrosis while increasing thickness as well as the number and average diameter of . The net effect was that tamoxifen raised the amount of contractile tissue available for respiration by 72%.

Patients with DMD show , and their muscle fibers become abnormally susceptible to stress. In this animal study, tamoxifen improved the structure of , slowed , increased overall muscle function, and made leg muscles more resistant to repetitive stimulation and fatigue. In fact, tamoxifen rendered dystrophic muscles even stronger than those of non-dystrophic . "Our findings of a slower rate of contraction and an enhanced resistance to fatigue in muscles from tamoxifen-treated dystrophic mice are of significance for the pathophysiology of muscular dystrophy," say the authors.

A wire test revealed that treating male mdx5Cv mice with tamoxifen for more than a year increased the whole body strength 2- to 3-fold, close to that of normal mice.

Additional findings shed light on the mechanism of tamoxifen's therapeutic actions. For example, plasma creatine kinase (CK) activity was found to be about 3 times higher in the dystrophic male mice than in the non-dystrophic males, and tamoxifen treatment normalized the CK levels of the dystrophic mice. The authors suggest that this effect is mediated by an estrogen receptor (ER) dependent mechanism. The study also reported for the first time that mouse dystrophic muscle is high in both ER α and β, and that tamoxifen raises levels of ERβ2 in particular. Other findings, such as increased levels of calcineurin and accumulation of several structural proteins, indicate a protective effect of tamoxifen on dystrophic muscles. The authors point out that the beneficial effects of tamoxifen were seen with muscle tissue levels much lower than those reported in previous studies of normal rodents, suggesting that doses lower than those used to treat breast cancer may be effective in the treatment of DMD.

Explore further: Treatment hope for Duchenne muscular dystrophy

More information: "The anti-cancer drug tamoxifen counteracts the pathology in a mouse model of Duchenne muscular dystrophy," by Olivier M. Dorchies, Julie Reutenauer-Patte, Elyes Dahmane, et al. (DOI: dx.doi.org/10.1016/j.ajpath.2012.10.018). It appears in The American Journal of Pathology, Volume 182, Issue 2 (February 2013)

Related Stories

Treatment hope for Duchenne muscular dystrophy

April 4, 2012

An international team led by the University of Melbourne Australia, has found that increasing a specific protein in muscles could help treat Duchenne muscular dystrophy (DMD), a severe and progressive muscle wasting disease ...

Recommended for you

Zika virus infection alters human and viral RNA

October 20, 2016

Researchers at University of California San Diego School of Medicine have discovered that Zika virus infection leads to modifications of both viral and human genetic material. These modifications—chemical tags known as ...

Food-poisoning bacteria may be behind Crohn's disease

October 19, 2016

People who retain a particular bacterium in their gut after a bout of food poisoning may be at an increased risk of developing Crohn's disease later in life, according to a new study led by researchers at McMaster University.

Neurodevelopmental model of Zika may provide rapid answers

October 19, 2016

A newly published study from researchers working in collaboration with the Regenerative Bioscience Center at the University of Georgia demonstrates fetal death and brain damage in early chick embryos similar to microcephaly—a ...

Scientists uncover new facets of Zika-related birth defects

October 17, 2016

In a study that could one day help eliminate the tragic birth defects caused by Zika virus, scientists from the Florida campus of The Scripps Research Institute (TSRI) have elucidated how the virus attacks the brains of newborns, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.